Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Arginine Metabolism & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARG2 (Arginase 2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARG2 Recombinant Protein (Full-length & Active Domain) — High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. Includes catalytic mutant variant for negative control. | View ARG2 Products |
| Gene Delivery | ARG2 Lentivirus Particles — Premade ORF for overexpression or shRNA for knockdown. Suitable for macrophage/MDSC model generation. | View ARG2 Products |
| Benchmark Ab | Anti-ARG2 (Research Grade) — Recombinant monoclonal for Western, ELISA, IHC validation. | View ARG2 Products |
| Validator | ARG2 siRNA Set (3 unique sequences) — For knockdown verification and specificity controls. | View ARG2 Products |
| Isoform Control: ARG1 | ARG1 Recombinant Protein — Essential for selectivity assays. High homology cross-screening control (>95% purity). | View ARG1 Products |
| Pathway Partner: NOS2 | NOS2/iNOS Recombinant Protein & Lentivirus — Competing pathway enzyme for arginine substrate competition studies. | View NOS2 Products |
| Related Target: PD-L1 | PD-L1 Recombinant Protein & Antibody — Synergistic immune checkpoint for combination therapy models. | View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (ARG2 vs ARG1) | Homolog Panel: Human ARG1 and ARG2 proteins with <0.1% cross-contamination, verified by mass spec peptide mapping. Critical for avoiding hepatic ARG1 inhibition. |
| Mitochondrial Localization Validation | Lentivirus-based stable ARG2-EGFP fusion lines for subcellular localization confirmation and high-content screening. |
| Cellular Mechanism Verification | siRNA & shRNA validation tools to confirm target engagement vs off-target effects in MDSC functional assays. |
| Substrate Competition Assays | Co-reagent availability: Recombinant NOS2 and ODC1 proteins for arginine/ornithine pathway competition studies. |
| False Positive Control | Catalytic mutant ARG2 protein (active-site disabled) available as negative control for counter-screening in enzymatic inhibitor assays. |
| Enzymatic Assay Reproducibility | Sequence Verified, Theoretical MW confirmed, rigorously Endotoxin Controlled. |
Live ARG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Arginase Inhibitors)
- ➤ Latest Resistance & Mechanism Research
- ➤ Recent Patent Filings (ARG2 Selective)
Global Clinical Landscape & Future Outlook
The first-generation pan-arginase inhibitors (e.g., CB-1158, INCB001158) have faced dose-limiting toxicities, particularly hyperammonemia due to hepatic ARG1 inhibition. This has catalyzed a shift toward highly selective ARG2 inhibitors that spare ARG1. Current clinical-stage programs focus on immuno-oncology combinations (e.g., with PD-1/PD-L1 checkpoint inhibitors) to reverse T-cell exhaustion in the tumor microenvironment (TME). Beyond oncology, ARG2’s role in mitochondrial signaling is being explored in fibrotic diseases (pulmonary fibrosis, liver fibrosis) and metabolic syndromes (diabetes, obesity). The next wave of R&D will require tissue-specific delivery strategies (e.g., inhalable formulations for lung fibrosis) and dual-target approaches (ARG2+ASS1, ARG2+NOS2) to overcome compensatory resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective ARG2) | Calithera Biosciences, early biotechs | Solid Tumors (MDSC targeting) | Isoform Selectivity Panel (ARG1 vs ARG2 enzymatic assays with >95% pure proteins) |
| Small Molecule (Dual ARG1/ARG2) | Incyte, OncoArendi | Advanced Solid Tumors | Dual enzyme counter-screening panel for balanced inhibition |
| siRNA / Gene Therapy | Specialized gene therapy firms | Hepatic/Metabolic Disease | Lentivirus delivery validation (mitochondrial-targeted ARG2 knockdown cell lines) |
| Allosteric Inhibitors | Academic/Discovery stage | Fibrosis, Autoimmune | Conformational protein panel (mutant ARG2 proteins for allosteric site mapping) |
| Combination Therapy | AstraZeneca, Merck | TME Immune Evasion (cold tumors) | Cell line validation (ARG2 overexpression lentivirus + PD-L1 co-culture models) |